Judicious modifications to the structure of the previously reported HCV NS5A inhibitor1, resulted in more potent anti-HCV compounds with similar and in some cases improved toxicity profiles. The synthesis of nineteen new NS5A inhibitors is reported along with their ability to block HCV replication in an HCV 1b replicon system. For the most potent compounds chemical stability, stability in liver microsomes and inhibition of relevantCYP450 enzymes is also presented.
3.3 log 10 ) after a single 100 mg dose with no signs of toxicity. 8 While compound 1 has established NS5A as a valid target for effective clinical treatment of HCV, it also provided a foundation for the design of second-generation inhibitors that could be more resistant to selection of mutant virus with reduced potential cytotoxic liabilities. This lead us to dissect the symmetrical inhibitor 1 into four major structural zones: zone I (biphenyl linker zone) has already been studied extensively by other research groups; zone II (imidazole portion) despite claims of small modifications no significant exploration of this area has been disclosed; zone III (proline moiety), minor modifications such as fluorination or cyclopropanation have been reported; zone IV (amino acid and its "cap") has been extensively studied. 8, 9 In consideration of novelty and retention of potency, we initially chose to focus on both zones II and III. Indeed, the lack of significant exploration of zone II along with the ease of halogenation of the imidazole ring, which would allow for the efficient preparation of more complex structures using transition metal catalyzed cross coupling reactions, made zone II ideal for investigation. Similarly, zone III has not been extensively explored while readily available proline analogs would allow for extensive modifications from well known organic transformations. Herein we wish to report our preliminary structure activity relationship (SAR) efforts for zones II and III.
The biphenyl core of the targeted compounds was prepared according to general Scheme 1. Diketone 1 was first converted to the α, α′-dibromodiketone using Br 2 in CH 2 Cl 2 then coupled with N-Boc protected proline derivatives A 10 Introduction of thiophene, furan or phenyl at the 4-position of the imidazole lead to a noticeable decrease of potency toward HCV replication (EC 50 of 100, 26 and 200 pM respectively) when compared to 1. Evaluation of the brominated intermediate 5a for antireplication activity versus HCV proved surprising as it displayed an EC 50 of 5.9 pM and EC 90 of 14 pM; thus compound 5a was equipotent to BMS-790052 at the EC 50 and EC 90 . This unexpected result prompted us to investigate the influence of other halogens at the 4position of the imidazole ring. Iodine and chlorine were thus introduced on the imidazole ring of compound 3a using N-iodosuccinimide (NIS) and N-chlorosuccinimide (NCS) respectively while fluorine was introduced by careful reaction with Nfluorobenzenesulfonimide (NFSI) and NaHCO 3 . It is noteworthy that this fluorination reaction leads to the formation of both the difluorinated derivative 4d and the monofluorinated derivative 4e. As above, simple Boc deprotection under acidic conditions followed by the coupling of N-methylcarbamate protected valine in the presence of HOBt and DIPEA resulted in the dihalogeneated compounds 5b-d and monofluoro derivative 5e. Remarkably the bis-iodo, bis-chloro and bis-fluoro compounds 5b, 5c and 5d exhibited an EC 50 of 6.4 ± 3.0, 5.5 ± 1.9 and 6.8 ± 3.3 pM respectively which, as in the case of the bisbromo compound, are equipotent to the reference compound 1. The EC 90 values for these three were all close to 10 pM representing a modest improvement relative to the reference compound 1. In addition, all of the bis-halogen compounds 5c and 5d exhibited increased toxicity in primary human lymphocytes, although they were non-toxic at concentrations up to 100 μM in Vero cells. These results suggest that a small modification in this region (Zone II) such as introduction of a halogen is well tolerated but introduction of larger groups such as thiophene, furane and phenyl are detrimental to the HCV replicon activity.
Zone III modifications (Scheme 3) included introduction of various triazoles using copper catalyzed alkyne azide cycloadditions. 12 Azido intermediates 3b and 3c were first deprotected under acidic conditions then coupled with N-methylcarbamate protected valine in presence of HOBt and DIPEA to give compounds 9-10 in respectively 64 and 59% yields. Finally, treatment of 9-10 with various alkenes in the presence of CuSO 4 and sodium ascorbate afforded the 1,4-triazolo derivatives 11-14 in good yields. Like for Zone II, introduction of bulky modifications such as 1,4-substituted triazoles on the proline moiety (Zone III) considerably decreased potencies. On the other hand, introduction of a small group such an azido group seems to be well tolerated. Indeed, (4-R)-azido compound 10 with an EC 50 = 9.5 pM appeared as potent as reference compound 1 without displaying any signs of toxicity up to 100 μM in PBM, CEM and Vero cells. Interestingly, (4-S)-azido compound 9 appeared slightly less active (EC 50 = 23 pM) and showed toxicities in PBM and CEM cells (IC 50 = 20.3 and 18.4 μM respectively).
Based on these results, a combination of our best modifications in both zone II and III was also studied. Thus, (4-S)-and (4-azido compounds 9 and 10 were halogenated at the R)azido compounds 9 and 10 were halogenated at the 4-position of the imidazoles rings by using either NBS or NCS in CH 2 Cl 2 (Scheme 4) and all the synthesized compounds displayed an EC 50 ≤ 10 pM. Interestingly, compound 17 showed an EC 50 of 2.6 pM with no toxicity toward Vero cells up to 100 μM.
Among all the molecules synthesized, the most promising compounds 5a-d were further investigated. First of all, their stability at pH 3 and 7 in phosphate buffer was evaluated. After 48 h at 20°C, LC/MS analysis at time 0, 1, 8, 24 and 48 h revealed no evidence of degradation of these compounds. Next stability in human liver microsomes was established ( Table 2 ). Compounds 5a-d (1 μM) were incubated with human liver microsomes in potassium phosphate buffer and 1 mg/mL microsomal protein. Samples were collected at 5, 15, 30 and 60 min, analyzed by LC-MS/MS and half-life (t 1/2 ) and intrinsic clearance (CL int ) for each compound were calculated based on the elimination rate constant (k). Interestingly, compounds 5b and 5d show higher metabolic stability and therefore lower clearance (CL int < 8.6) compared with BMS-790052.
Drug-drug interactions have become an important issue in modern health care. It is now apparent that many drug-drug interactions can be explained by alterations in the metabolic lenzymes that are present in the liver and other extra-hepatic tissues. Many of the major pharmacokinetic interactions between drugs are due to hepatic cytochrome P450 (CYP450) enzymes being affected by one or more of the drugs present in a given individual. Furthermore, drug interactions can be a result of inhibition or induction of CYP450 enzymes. The potential drug-drug interaction liabilities of these compounds were investigated by a CYP450 reversible inhibition assay. Compounds 5b and 5d did not appear to inhibit the major CYP450 enzymes at the IC 90 level and had a favorable CYP profile, which is suggestive of no potential drug-drug interactions ( Table 3 ). Due to the large therapeutic window, the inhibition observed for 3A4 (in the micromolar range) is expected not to be clinically relevant at therapeutic doses.
Initial resistant virus selection studies using 5b and BMS-790052 were performed and mutations identified by population sequencing. Mutations observed for BMS-790052 included L31V, which was previously reported, 13 in addition to several unreported mutations, which we will disclose in full detail in subsequent publications. Compound 5b selected for several different mutations including Y93H, which was previously reported as an NS5A resistance mutation. 13 In conclusion, extremely potent new NS5A inhibitors (picomolar activity) with a wide therapeutic window (> 10 4 ) are disclosed. Among all the compounds prepared 5b and 5d exhibited improved liver microsome stability compared to reference compound BMS-790052 and no inhibition of major human CYP enzymes was exhibited at therapeutically relevant concentrations. In addition, these two halogenated compounds displayed improved stability toward human liver microsomes versus BMS-790052 while maintaining comparable anti-HCV replication activity. Finally, further mutation selection studies are currently being investigated in our laboratory and will be the subject of future publications. 
